Phosphate sandoz ( DrugBank: Phosphate )

1 disease
告示番号疾患名（ページ内リンク）臨床試験数
78下垂体前葉機能低下症1

78. 下垂体前葉機能低下症

臨床試験数 : 492 /  薬物数 : 341 - (DrugBank : 47) / 標的遺伝子数 : 45 - 標的パスウェイ数 : 100
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2005-004316-73-GB
(EUCTR)		23/08/200612/12/2005The effects of growth hormone, strontium ranelate and phosphate on PTH circadian rhythm, PTH target organ sensitivity, bone turnover markers, phospho-calcium metabolism and bone mineral density. A prospective, open labelled study. - Effects of anabolic therapies on PTH circadian rhythm & sensitivityThe effects of growth hormone, strontium ranelate and phosphate on PTH circadian rhythm, PTH target organ sensitivity, bone turnover markers, phospho-calcium metabolism and bone mineral density. A prospective, open labelled study. - Effects of anabolic therapies on PTH circadian rhythm & sensitivity Osteoporosis and Reduced Bone mineral density (T scores< -1.0 on DEXA scan), Adult growth hormone deficiency ( GH levels,9mU/l on Insulin stress test) with reduced BMD (T scores< -1.0 on DEXA scan)Product Name: strontium ranelate
Product Code: strontium ranelate
INN or Proposed INN: strontium ranelate
Other descriptive name: N/A
Product Name: Phosphate sandoz
Product Code: phosphate sandoz
INN or Proposed INN: phosphate sandoz
Other descriptive name: N/A
Product Name: growth hormone
Product Code: growth hormone
INN or Proposed INN: growth hormone
Other descriptive name: N/A		Royal Liverpool University hospitalNULLNot Recruiting Female: yes
Male: yes		100 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yesUnited Kingdom